FibroGen (FGEN) Stock Price Down 4.1%

FibroGen Inc (NASDAQ:FGEN) shares traded down 4.1% on Tuesday . The company traded as low as $41.46 and last traded at $39.91. 650,858 shares changed hands during mid-day trading, an increase of 15% from the average session volume of 567,351 shares. The stock had previously closed at $41.62.

A number of research analysts have recently weighed in on the company. Leerink Swann set a $84.00 price target on FibroGen and gave the company a “buy” rating in a research note on Monday, October 15th. ValuEngine downgraded FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 17th. BidaskClub downgraded FibroGen from a “buy” rating to a “hold” rating in a research note on Tuesday, October 23rd. Citigroup downgraded FibroGen from a “buy” rating to a “hold” rating and set a $71.00 price target on the stock. in a research note on Wednesday, August 8th. Finally, Zacks Investment Research raised FibroGen from a “sell” rating to a “hold” rating in a research note on Tuesday, July 10th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $72.25.

The company has a market capitalization of $3.34 billion, a P/E ratio of -25.66 and a beta of 1.81. The company has a quick ratio of 7.95, a current ratio of 7.95 and a debt-to-equity ratio of 0.19.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.31. The business had revenue of $43.95 million for the quarter, compared to the consensus estimate of $28.70 million. FibroGen had a negative return on equity of 22.60% and a negative net margin of 85.59%. Equities research analysts predict that FibroGen Inc will post -1.05 earnings per share for the current year.

In related news, Director Roberto Pedro Rosenkranz sold 1,000 shares of the firm’s stock in a transaction on Thursday, September 20th. The stock was sold at an average price of $56.95, for a total transaction of $56,950.00. Following the sale, the director now owns 33,700 shares of the company’s stock, valued at approximately $1,919,215. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Thomas B. Neff sold 18,900 shares of the firm’s stock in a transaction on Thursday, October 18th. The stock was sold at an average price of $54.52, for a total value of $1,030,428.00. Following the sale, the chief executive officer now directly owns 2,710,412 shares in the company, valued at approximately $147,771,662.24. The disclosure for this sale can be found here. Insiders have sold a total of 197,037 shares of company stock worth $11,508,834 in the last ninety days. 8.96% of the stock is currently owned by company insiders.

Institutional investors have recently modified their holdings of the stock. Rothschild Asset Management Inc. increased its holdings in FibroGen by 0.9% during the 2nd quarter. Rothschild Asset Management Inc. now owns 149,239 shares of the biopharmaceutical company’s stock worth $9,342,000 after purchasing an additional 1,349 shares in the last quarter. Strs Ohio increased its holdings in FibroGen by 0.8% during the 2nd quarter. Strs Ohio now owns 186,300 shares of the biopharmaceutical company’s stock worth $11,662,000 after purchasing an additional 1,400 shares in the last quarter. Allianz Asset Management GmbH increased its holdings in FibroGen by 14.6% during the 1st quarter. Allianz Asset Management GmbH now owns 11,506 shares of the biopharmaceutical company’s stock worth $532,000 after purchasing an additional 1,462 shares in the last quarter. Hilltop Holdings Inc. increased its holdings in FibroGen by 2.9% during the 2nd quarter. Hilltop Holdings Inc. now owns 55,140 shares of the biopharmaceutical company’s stock worth $3,452,000 after purchasing an additional 1,530 shares in the last quarter. Finally, Raymond James & Associates increased its holdings in FibroGen by 14.2% during the 2nd quarter. Raymond James & Associates now owns 13,174 shares of the biopharmaceutical company’s stock worth $825,000 after purchasing an additional 1,640 shares in the last quarter. 76.09% of the stock is currently owned by institutional investors and hedge funds.

About FibroGen (NASDAQ:FGEN)

FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.

Read More: Fundamental Analysis – How It Helps Investors

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply